Literature DB >> 16424648

Splenectomy for chronic idiopathic thrombocytopenic purpura in children: a single center study in China.

Tingting Wang1, Maoqiang Xu, Linxiang Ji, Renchi Yang.   

Abstract

The management of chronic and refractory idiopathic thrombocytopenic purpura (ITP) in children is controversial. We conducted a retrospective review of our single center experience in China between 1990 and 2003 with splenectomy for chronic ITP in children in order to determine the initial and long-term hematological response, morbidity, mortality, predictors of response to splenectomy and the therapy in children who failed splenectomy. Of 65 children analyzed, the overall immediate clinical response to splenectomy was 89.2%. The median postsplenectomy follow-up time was 52 months (8-124). During follow-up, 9 children (13.8%) relapsed within a median time of 6 months (2-58). The overall morbidity was 1.5% and perioperative mortality was zero. During follow-up, 1 child died of intracranial hemorrhage (ICH) and 1 died of overwhelming postsplenectomy infection (OPSI). The platelet count at day 7 after splenectomy was a predictor of a sustained response to splenectomy but no preoperative parameters were predictors of the response to splenectomy. Of the 15 children who failed splenectomy, excluding the one who died of ICH, only 2 children intermittently required corticosteroids and IVIG. Splenectomy is a potential therapy to provide long-term control of disease in children with chronic ITP and is associated with low morbidity and mortality. The risk of fulminant sepsis remains an omnipresent concern. Antipneumococcal vaccination and antibiotic prophylaxis should be recommended and children should receive timely and adequate antibiotics for bacteria infection to lessen the problem of OPSI. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16424648     DOI: 10.1159/000089464

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  5 in total

Review 1.  Evidence-based management of immune thrombocytopenia: ASH guideline update.

Authors:  Cindy E Neunert; Nichola Cooper
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  A cost-effectiveness study of intravenous immunoglobulin in childhood idiopathic thrombocytopenia purpura patients with life-threatening bleeding.

Authors:  Rosarin Sruamsiri; Piyameth Dilokthornsakul; Chayanin Pratoomsoot; Nathorn Chaiyakunapruk
Journal:  Pharmacoeconomics       Date:  2014-08       Impact factor: 4.981

3.  Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.

Authors:  Cindy Neunert; Jenny Despotovic; Kristina Haley; Michele P Lambert; Kerri Nottage; Kristin Shimano; Carolyn Bennett; Robert Klaassen; Kimo Stine; Alexis Thompson; Yves Pastore; Travis Brown; Peter W Forbes; Rachael F Grace
Journal:  Pediatr Blood Cancer       Date:  2016-05-02       Impact factor: 3.167

4.  American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Authors:  Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely
Journal:  Blood Adv       Date:  2019-12-10

5.  Increased Risk of Hemorrhagic and Ischemic Strokes in Patients With Splenic Injury and Splenectomy: A Nationwide Cohort Study.

Authors:  Jiun-Nong Lin; Cheng-Li Lin; Ming-Chia Lin; Chung-Hsu Lai; Hsi-Hsun Lin; Chih-Hui Yang; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.